Abstract
Hypoxia-inducible factor-1α (HIF-1α) and signal transducer and activator of transcription 3 (STAT3) are transcription factors and are activated in response to hypoxia. Both HIF-1α and STAT3 regulate various aspects of cancer biology such as cell survival, proliferation, angiogenesis etc. and are constitutively expressed in a wide range of human cancers. In the last decade, over expression of HIF-1α and STAT3 has been demonstrated in many common human cancers, thereby emerging as highly compelling anticancer targets for drug discovery. We herein report the design and synthesis of new imidazopyridine based potent dual inhibitors of HIF-1α and STAT3 pathways. The lead compound of this series P3971 has been identified as a potent inhibitor of HIF-1α (200 nM) and STAT3 (350 nM) with significant antiproliferative activity against various cancer cell lines. Moreover, P3971 was also found to be orally efficacious in HCT116 (colon cancer) and H460 (lung cancer) xenograft mice models.
Keywords: Anticancer, drug discovery, HIF-1α, STAT3, imidazopyridine.
Anti-Cancer Agents in Medicinal Chemistry
Title:Discovery of P3971 an Orally Efficacious Novel Anticancer Agent Targeting HIF-1α and STAT3 Pathways
Volume: 13 Issue: 9
Author(s): Pallavi Godse, Pramod Kumar, Nilambari Yewalkar, Vijaykumar Deore, Manoj Lohar, Ramswaroop Mundada, Amol Padgaonkar, Sonal Manohar, Asavari Joshi, Dimple Bhatia, Nikesh Desai, Anagha Damre, Mandar Bhonde, Kalpana Joshi, Rajiv Sharma and Sanjay Kumar
Affiliation:
Keywords: Anticancer, drug discovery, HIF-1α, STAT3, imidazopyridine.
Abstract: Hypoxia-inducible factor-1α (HIF-1α) and signal transducer and activator of transcription 3 (STAT3) are transcription factors and are activated in response to hypoxia. Both HIF-1α and STAT3 regulate various aspects of cancer biology such as cell survival, proliferation, angiogenesis etc. and are constitutively expressed in a wide range of human cancers. In the last decade, over expression of HIF-1α and STAT3 has been demonstrated in many common human cancers, thereby emerging as highly compelling anticancer targets for drug discovery. We herein report the design and synthesis of new imidazopyridine based potent dual inhibitors of HIF-1α and STAT3 pathways. The lead compound of this series P3971 has been identified as a potent inhibitor of HIF-1α (200 nM) and STAT3 (350 nM) with significant antiproliferative activity against various cancer cell lines. Moreover, P3971 was also found to be orally efficacious in HCT116 (colon cancer) and H460 (lung cancer) xenograft mice models.
Export Options
About this article
Cite this article as:
Godse Pallavi, Kumar Pramod, Yewalkar Nilambari, Deore Vijaykumar, Lohar Manoj, Mundada Ramswaroop, Padgaonkar Amol, Manohar Sonal, Joshi Asavari, Bhatia Dimple, Desai Nikesh, Damre Anagha, Bhonde Mandar, Joshi Kalpana, Sharma Rajiv and Kumar Sanjay, Discovery of P3971 an Orally Efficacious Novel Anticancer Agent Targeting HIF-1α and STAT3 Pathways, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (9) . https://dx.doi.org/10.2174/18715206113136660341
DOI https://dx.doi.org/10.2174/18715206113136660341 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Status of Programmed Death Ligand 1 (PD-L1) by Immunohistochemistry and Scoring Algorithms
Current Drug Targets Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Therapeutic Potential of Adipose-derived Stem Cells in the Treatment of Pulmonary Diseases
Current Stem Cell Research & Therapy Fluorescence Imaging in Cancerology
Current Molecular Imaging (Discontinued) Updates for Chest Tumors
Current Cancer Therapy Reviews A Computer - Aided Drug Designing for Pharmacological Inhibition of Mutant ALK for the Treatment of Non-small Cell Lung Cancer
Current Topics in Medicinal Chemistry Drug Treatment of Obesity: Established and Emerging Therapies
Mini-Reviews in Medicinal Chemistry Platinum(II) and Palladium(II) Complex Compounds as Anti-cancer Drugs. Methods of Cytotoxicity Determination
Current Pharmaceutical Analysis Graphene Oxide-Based Nanocarriers for Cancer Imaging and Drug Delivery
Current Pharmaceutical Design Repurposing Drugs for Cancer Prevention
Current Topics in Medicinal Chemistry Angiogenesis Inhibitors: Implications for Combination with Conventional Therapies
Current Pharmaceutical Design What We Learnt from Randomized Clinical Trials and Cohort Studies of Antioxidant Vitamin? : Focus on Vitamin E and Cardiovascular Disease
Current Pharmaceutical Biotechnology Antineoplastic Activity of Monocrotaline Against Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Clinical Importance of Assessment of Type 2 Diabetes Mellitus with Visceral Obesity. A Japanese Perspective
Current Diabetes Reviews Tyrosine Kinase Inhibitors: A Potential Approach to the Treatment of Hepatocellular Carcinoma
Current Pharmaceutical Design AKT and cytosolic phospholipase A<sub>2</sub>α form a positive loop in prostate cancer cells
Current Cancer Drug Targets Radiolabeled Oligonucleotides for Antisense Imaging
Current Organic Synthesis The Role of Clusterin in Carcinogenesis and its Potential Utility as Therapeutic Target
Current Medicinal Chemistry Nucleoside Phosphorylases
Current Organic Chemistry Oxidative stress in carcinogenesis: new synthetic compounds with dual effects upon free radicals and cancer.
Current Medicinal Chemistry